Research and Development

Develops drugs which block intracellular signal transduction pathways for treating solid tumors and hematologic malignancies. Includes kits available, technology overview and investor data from Cambridge, Massachusetts. (Nasdaq: ARIA)

Category:

Random Site Quote:

ARIAD is developing breakthrough medicines that regulate cell-signaling pathways implicated in cancer. Our pipeline includes a series of small molecule product candidates that provide targeted and highly potent anti-cancer activity to treat solid tumors and hematologic cancers, as well as the spread of tumors to distant sites. Our lead candidate Â— ridaforolimus, a novel mTOR inhibitorÂ—has been given fast track designation by the FDA for the treatment of soft-tissue and bone sarcomas.
ARIAD is dedicated to developing new, breakthrough therapies with the potential to transform the lives of patients with difficult-to-treat cancers. ARIAD scientists and clinical researchers are experts with specialized knowledge in oncology’s most challenging areas, including blood cancers

Date Added: Apr 2, 2011 Hits: Rating: 0.00 Votes: 0

Member Reviews

Visitor Ratings

Google PR

2. Arqule, Inc.

Promotes their activated checkpoint therapy platform. Headquartered in Woburn, Massachusetts. (Nasdaq: ARQL)

Category:

Random Site Quote:

Investor & Media Relations We are pursuing a number of exciting and innovative approaches to cancer therapy at ArQule. These are the result of unique biology and world-class chemistry capabilities that differentiate us from other development-stage oncology companies. We are also moving rapidly
For detailed information visit the website, please...

Date Added: Apr 2, 2011 Hits: Rating: 0.00 Votes: 0

Member Reviews

Visitor Ratings

Google PR

3. Draxis Health Inc.

Produces radiolabeled compounds for diagnostic and therapeutic use in nuclear medicine and oncology. Includes examples that distinguish infection from inflammation, a peptide based on fibrin, and overview of facilities in Kirkland, QuA©bec. [English, French and Spanish]

Category:

Random Site Quote:

DraxImage High Quality Radiopharmaceuticals - a division of DRAXIS Speciality Pharmaceuticals Inc. A Jubilant Organosys Company.
At DRAXIMAGE, we are passionately dedicated to the field of Nuclear medicine. Our mission is to discover, develop, manufacture and market innovative diagnostic and therapeutic radiopharmaceuticals and other technologies used in our field of expertise. DTPA+, Gluceptate, MAA, MDP+ and Sestamibi kits

Date Added: Apr 2, 2011 Hits: Rating: 0.00 Votes: 0

Member Reviews

Visitor Ratings

Google PR

4. Exelixis, Inc.

Genomics-based discovery company focused on development of drugs, crop protection, and plant biotechnology. Overview of research, investor relations and contacts in California and Portland, Oregon. (Nasdaq: EXEL)

Category:

Random Site Quote:

Weâ€™ve had a busy and productive few months at Exelixis, and the diligent efforts of our team are already producing exciting results for our company. On November 4, we reported our financial results for the third quarter, which reflected reductions in our operating expenses and net loss, despite
For detailed information visit the website, please...

Date Added: Apr 2, 2011 Hits: Rating: 0.00 Votes: 0

Member Reviews

Visitor Ratings

Google PR

5. Genaera Corp.

Develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. Includes overview of clinical trials, investor information and news from company in Plymouth Meeting, Pennsylvania. (Nasdaq: GENR)

Category:

Random Site Quote:

On June 12, 2009, Genaera Corporation transferred all of its assets and liabilities to the Genaera Liquidating Trust in accordance with the Plan of Complete Liquidation and Dissolution adopted at a Special Meeting of Stockholders on June 4, 2009. Persons having business with Genaera Corporation or
For detailed information visit the website, please...

Date Added: Apr 2, 2011 Hits: Rating: 0.00 Votes: 0

Member Reviews

Visitor Ratings

Google PR

6. ImmunoGen, Inc.

Licenses tumor-activated prodrug technology, for development of small molecule anticancer agents, to optimise potency and toxicity. Manufacturing in Norwood, and headquarters in Cambridge, Massachusetts. (Nasdaq: IMGN)

Category:

Random Site Quote:

ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Targeted Antibody Payload (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies. Listen to our Feb. 25 Analyst & Investor
For detailed information visit the website, please...

Date Added: Apr 2, 2011 Hits: Rating: 0.00 Votes: 0

Member Reviews

Visitor Ratings

Google PR

7. Dendreon Corp.

Discovers and develops immunologically based therapeutic anticancer products. Includes progress of clinical trials, and data for investors from company based in Seattle, Washington. (Nasdaq: DNDN)

Category:

Random Site Quote:

PROVENGE ® Is Now Available PROVENGE is the first FDA-approved autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. With every step of this journey, patients have been our inspiration...
For detailed information visit the website, please...

Date Added: Apr 2, 2011 Hits: Rating: 0.00 Votes: 0

Member Reviews

Visitor Ratings

Google PR

8. OSI Pharmaceuticals Inc.

Researches and develops diagnostics and anticancer therapy in humans and other diseases associated with control of cell growth. Laboratories in Oxford, Boulder and Farmingdale, headquartered in Melville, New York. (Nasdaq: OSIP)

Category:

Random Site Quote:

OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality, novel and differentiated personalized medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.
Tarceva Â® (erlotinib) tablets Now FDA-approved as maintenance therapy for NSCLC Tarceva monotherapy is indicated as maintenance treatment in patients with locally advanced or metastatic NSCLC who disease has not progressed after four cycles of platinum-based first-line chemotherapy. Tarceva is

Date Added: Apr 2, 2011 Hits: Rating: 0.00 Votes: 0

Member Reviews

Visitor Ratings

Google PR

9. Panacea Pharmaceuticals, Inc.

Focused on utilizing functional genomics and proteomics to develop therapeutic agents and diagnostic tests for diseases with substantial unmet clinical need.

Category:

Random Site Quote:

Panacea's is focused on novel proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, stroke, Alzheimer's Disease, and Parkinson's Disease.
Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies is to discover, develop and commercialize innovative therapeutic and diagnostic products. Our current product development focus is on novel proteins and biochemical pathways related to cellular regulation

Date Added: Apr 2, 2011 Hits: Rating: 0.00 Votes: 0

Member Reviews

Visitor Ratings

Google PR

10. Heal Corporation

Details of projects using resistance related to polyunsaturated fatty acids and catalase in vitro, applied in vivo to trout model. Includes publications, charity status, facilities and contacts in Olympia, Washington.

Category: